C4 Therapeutics reports Q2 2026 results, cemsidomide trials on track for 2027 dataAug 11Quarterly updateC4 Therapeutics, Inc.cemsidomide
Bristol Myers Squibb raises 2026 guidance, cites pipeline progress across four programsJul 30Quarterly updateBristol Myers Squibbluspatercept
Karuna/BMS opens Phase 3 KarXT relapse prevention trial in schizophreniaJul 7Weekly roundup, 2 itemsBristol Myers Squibbpomalidomide
Sign inSign in